NCT06916156 - Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

August 14, 2025

Study Completion Date

August 19, 2025

Conditions

Pharmacokinetics Study on Healthy Volunteers Adults

Interventions

DRUG

ANT3310

ANT3310 will be administered in combination with Meropenem. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.

DRUG

Meropenem

Meropenem will be administered in combination with ANT3310. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.

Trial Locations (1)

85032

Pulmonary Associates, PA, Phoenix